One Factory Between the Drug and Nothing

Sterile injectable drugs account for 20–80% of all drug shortages in the United States, with median shortage duration of 4.6 years compared to 1.6 years for oral drugs. Approximately 40% of generic injectable drug markets have only a single manufacturer, and manufacturing facilities typically operate above 80% capacity, leaving no surge capability when a facility goes offline for contamination, equipment failure, or regulatory action. Unlike oral drugs, sterile injectables require aseptic manufacturing environments where a single contamination event can shut down an entire production line for months to years of remediation.

Sterile injectables include essential hospital drugs — anesthetics (propofol), vasopressors (norepinephrine), chemotherapy agents, electrolyte solutions, and sedatives — where shortage means delayed surgeries, rationed cancer treatment, and preventable deaths. The FDA Drug Shortages Database has listed 100+ injectable shortages annually since 2018. During COVID-19, sedative and paralytic shortages for mechanically ventilated patients directly constrained ICU capacity. The problem is structurally self-reinforcing: generic injectable prices are driven so low by competitive bidding that manufacturers cannot invest in redundancy, quality improvements, or modern facilities.

The FDA CARES Act (2020) added shortage notification requirements but cannot compel manufacturers to maintain production. The Drug Quality and Security Act (2013) enhanced inspection authority after the NECC compounding pharmacy contamination that killed 76 people, but regulatory enforcement further concentrates production — closing substandard facilities without expanding capacity. "Quality Maturity" voluntary programs exist but adoption is limited because manufacturers face no financial return on quality investment above minimum compliance. Proposals for government strategic reserves face the constraint that most injectables have limited shelf life (months to a few years) and require cold chain storage, making stockpiling expensive and wasteful.

Modular, smaller-scale aseptic manufacturing systems — continuous manufacturing platforms, closed single-use bioreactor systems — that reduce the capital and operational cost of maintaining redundant production capacity. Rapid fill-finish platforms that could be activated during shortages, analogous to emergency vaccine manufacturing surge capacity developed during COVID-19. Real-time supply chain visibility tools that predict shortages before they reach hospitals by monitoring production capacity utilization, quality system signals, and API supplier status across the manufacturing network.

A student team could map the complete supply chain for one critical injectable drug (e.g., norepinephrine or propofol) to identify all single-point-of-failure nodes — from API sourcing through fill-finish to hospital delivery — and quantify the vulnerability at each node. Alternatively, teams could design a modular aseptic fill-finish cell concept using single-use technology that could be deployed for emergency production. Relevant disciplines: pharmaceutical engineering, industrial engineering, supply chain management, biomedical engineering.